MREO has been granted a new patent
Sep 18, 2024, 10:40 PM
8.06%
What does MREO do
Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
MREO filed a patent for "use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta" on Fri, April 7, 2023. The patent was officially published on Thu, November 16, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.